Atrial Appendage

A database review showed left atrial appendage closure with the Watchman device is safe in adults with HF and atrial fibrillation, who experienced in-hospital mortality and CV complication rates similar to those without HF.

BOSTON — At 3 years, the Amplatzer Amulet device remained superior at left atrial appendage occlusion and noninferior for safety and effectiveness compared with the Watchman device, researchers reported at TCT 2022.

Same-day discharge did not raise risk for readmission in patients with atrial fibrillation who underwent left atrial appendage closure without complications, researchers reported.

Acutus Medical announced the FDA clearance and commercial launch of its new left-heart access system for use with the Boston Scientific’s left atrial appendage closure device.

After left atrial appendage occlusion with a next-generation device, patients with atrial fibrillation had similar outcomes at 45 days regardless of medication regimen, researchers reported at TVT: The Structural Heart Summit.

A next-generation left atrial appendage closure device conferred low rates of adverse events and peri-device leak in a real-world cohort at 45 days, according to results of the SURPASS study.

The Lariat left atrial appendage ligation device was safe and successful at excluding the left atrial appendage in patients with persistent atrial fibrillation, researchers reported at the American Heart Association Scientific Sessions.

The FDA has issued a letter to health care providers in response to a recent study that evaluated differences in procedural outcomes between women and men undergoing left atrial appendage occlusion device implantation.

Abbott announced the FDA approval of its left atrial appendage occlusion device for the treatment of atrial fibrillation in patients at risk for ischemic stroke.

The FDA has approved a second-generation left atrial appendage closure device for patients with nonvalvular atrial fibrillation, Boston Scientific announced.